COVID-19 vaccines not linked to pregnancy loss; mixing vaccines may confer greater protection

COVID-19 vaccines not linked to pregnancy loss; mixing vaccines may confer greater protection

22/10/2021 10:49:00 PM

COVID-19 vaccines not linked to pregnancy loss; mixing vaccines may confer greater protection

The following is a summary of some recent studies on COVID-19. They include research that warrants further study to corroborate the findings and that have yet to be certified by peer review.COVID-19 vaccines not linked with pregnancy lossTwo studies in major medical journals add to evidence that CO

COVID-19 vaccines not linked with pregnancy lossTwo studies in major medical journals add to evidence that COVID-19 vaccines are safe before and during pregnancy. One study, published in The New England Journal of Medicine on Wednesday, tracked nearly 18,500 pregnant women in Norway, including about 4,500 who had miscarriages. Researchers found no link between COVID-19 vaccines and risk of first-trimester miscarriage, regardless of whether the vaccines were from Moderna, Pfizer and BioNTech, or AstraZeneca. Overall, the women with miscarriages were 9per cent less likely to have been vaccinated, according to the researchers' calculations. In a separate study published on Thursday in The Lancet, researchers tracked 107 women who became pregnant while participating in trials of AstraZeneca's vaccine in the UK, Brazil and South Africa. Seventy-two of the women had received the vaccine while the others got a placebo. AstraZeneca's vaccine had no effect on the odds of safely carrying the pregnancy to term, the researchers reported."It is important that pregnant women are vaccinated since they have a higher risk of hospitalizations and COVID-19-complications, and their infants are at higher risk of being born too early," the authors of the Norwegian study wrote."Also, vaccination during pregnancy is likely to provide protection to the newborn infant against COVID-19 infection in the first months after birth."

Blackpink’s Lisa walks her first fashion runway for Celine Myanmar security forces ram car into protest in Yangon, deaths feared Smouldering debris, mud hinder Indonesia volcano rescue; at least 14 dead

Vaccine combinations with different technologies may be bestHealthcare workers in France who got a first shot of AstraZeneca's COVID-19 vaccine and then the Pfizer/BioNTech vaccine for their second shot showed stronger immune responses than those who had received two shots of the Pfizer vaccine, in a recent study. Combining different technologies is known to boost immune responses to other viruses, and the current study suggests it may be true for the coronavirus as well. Both vaccines in the study deliver instructions that teach cells in the body to make a piece of protein that resembles the spike on the coronavirus and that triggers an immune response. But they do it in very different ways. Both protocols provided"safe and efficient" protection, said Vincent Legros of Universite de Lyon in France, coauthor of a report published on Thursday in Nature. But combining the AstraZeneca shot with the Pfizer/BioNTech vaccine"conferred even better protection" than two doses of Pfizer's shot, including against the Delta variant, Legros said. The two technologies combined induced an antibody response of better quality, with more neutralizing antibodies that could block the virus, and more cells that have been"trained" by the vaccine to have increased defense potential, he said. Combination vaccination"is safe and may provide interesting options... for clinicians to prevent SARS-CoV-2 infection," Legros concluded.

Cognitive problems seen in middle-aged COVID-19 survivorsA"substantial proportion" of middle-aged COVID-19 survivors with no previous dementia had cognitive problems more than half a year after diagnosis, researchers have found. They looked at 740 people who ranged in age from 38 to 59. About half were white, and 63per cent were female. On tests of thinking skills, 20per cent had trouble converting short-term memories to long-term memories, 18per cent had trouble processing information rapidly, and 16per cent had trouble with skills needed for planning, focusing attention, remembering instructions, and juggling multiple tasks. The average time from diagnosis was 7.6 months. About one-in-four patients had been hospitalized, but most of them were not critically ill."We can't exactly say that the cognitive issues were lasting because we can't determine when they began," said Dr. Jacqueline Becker of the Icahn School of Medicine at Mount Sinai in New York City, who co-led the study published on Friday in JAMA Network Open."But we can say that our cohort had higher than anticipated frequency of cognitive impairment" given that they were relatively young and healthy, Becker said.

Data support use of Pfizer vaccine in children and teensThe Pfizer/BioNTech COVID-19 vaccine showed 90.7per cent efficacy against the coronavirus in a trial of children ages 5 to 11, the U.S. drugmaker said on Friday in briefing documents submitted to the U.S. Food and Drug Administration but not formally published. The children were given two shots of a 10-microgram dose of the vaccine - a third of the strength given to people 12 and older. The study was not primarily designed to measure efficacy against the virus. Instead, it compared the amount of neutralizing antibodies induced by the vaccine in the children to the response of recipients in their adult trial. Pfizer and BioNTech said the vaccine induced a robust immune response in the children. Outside advisers to the FDA are scheduled to meet on Tuesday to vote on whether to recommend authorization of the vaccine for that age group. A separate study from Israel conducted while the Delta variant was prevalent and published on Wednesday in The New England Journal of Medicine, compared nearly 95,000 12- to -18-year-olds who had received Pfizer's vaccine with an equal number of adolescents who had not been vaccinated. The results show the vaccine"was highly effective in the first few weeks after vaccination against both documented infection and symptomatic COVID-19 with the Delta variant" in this age group, the research team reported.

Click for a Reuters graphic on vaccines in development.(Reporting by Nancy Lapid; Additional reporting by Michael Erman; Editing by Bill Berkrot) Read more: CNA »

JI arrests, 20 years on: ISD releases new details on terrorist group’s plans to attack nearly 80 S’pore targets

SINGAPORE — The Internal Security Department (ISD) has released newly declassified details of terror plans by the Jemaah Islamiyah (JI) organisation against about 80 targets here. These include previously unreleased statements by JI detainees and surveillance footage obtained by the group as it plotted against Singapore.

Kopitiam, Delifrance among 24 F&B outlets penalised for breaching Covid-19 measuresSINGAPORE - Kopitiam and Delifrance were among 24 food and beverage (F&B) outlets penalised for breaching Covid-19 safe management measures in the past two weeks. Fifteen of these outlets were ordered to close and the remaining nine were fined, said the Ministry of... Sometimes the restaurants find it difficult to maintain the distance. The customers are unreasonable at times and the staff will find it difficult to remind someone who rebuts them.

Covid-19: Rise in cases and deaths tests Britain’s gamble on few virus restrictionsSpore in exact situation. So make sure nobody dies that is the only solution

Many Indians unlikely to be fully vaccinated by year-end despite ample COVID-19 shotsNEW DELHI: Tens of millions of Indian adults are unlikely to be fully vaccinated against COVID-19 by the end of 2021 despite ample supplies, due to an unusually large gap between the doses of the most widely-used vaccine and growing complacency as cases fall. The locally-produced AstraZeneca vaccine,

‘Mr POSB’ Bertie Cheng dies from Covid-19; son urges seniors to get vaccinatedSINGAPORE — Known by some as “Mr POSB”, the former chief executive officer (CEO) of the bank Bertie Cheng Shao Shiong died on Friday morning (Oct 22) from Covid-19 at the age of 84.

Parts of China toughen Covid-19 curbs to fight new outbreak

Germany warns of 'escalation' in COVID-19 casesBERLIN: Germany\u0027s health ministry said on Friday (Oct 22) the country was seeing a surge in coronavirus infections and warned that the situation was likely to worsen as winter approaches. \u0022With the rising infection numbers we are seeing an escalation of the situation,\u0022 health ministry spokesman Oliver Ewal Imported cases from Singapore.